The National Health Surveillance Agency (Anvisa) received on Thursday a request for emergency use of a drug against Covid-19 as a result of the combination of casirivimab and imdevimab, the agency said on Friday.
The drug belongs to the pharmaceutical group Roche. Anvisa said it will start sorting the documents present in the order.
“Anvisa will evaluate the request for authorization for the emergency and temporary use of medication against Covid-19, within a period of up to 30 (thirty) days, the analysis does not consider the time of the process in technical requirement status, which is when the laboratory needs to answer technical questions asked by the Agency within the process ”, informed the agency on its website.
Last month, Anvisa approved the use of remdesivir, by the pharmaceutical Gilead, against Covid-19, the first registration for a drug with use indicated in package inserts for the treatment of the disease.
Do you want to find out how it is possible to multiply your capital in the Options market? The analyst Fernando Góes shows you how in Week 3 × 1, online event and 100% free. Click here to watch.
Get the latest news delivered to your inbox
Follow us on social media networks